PCOS and intimacy

Polycystic ovary syndrome (PCOS) is the most common endocrine disorder in people of reproductive age, affecting an estimated 8–13% depending on the criteria used, with up to 70% undiagnosed worldwide (WHO, 2023).

Diagnosis

Under the Rotterdam criteria, endorsed by the 2023 International Evidence-Based Guideline, diagnosis requires two of three:

1. Irregular or absent ovulation
2. Clinical or biochemical hyperandrogenism (acne, hirsutism, raised free testosterone)
3. Polycystic ovarian morphology on ultrasound, or raised anti-Müllerian hormone (AMH), which the 2023 guideline accepted as an alternative to ultrasound

Ultrasound should not be used for diagnosis within 8 years of menarche, because multifollicular ovaries are normal in adolescence. Other causes — thyroid disease, hyperprolactinaemia, congenital adrenal hyperplasia — must be excluded.

Despite the name, the "cysts" are not cysts; they are ordinary immature follicles.

Effects on sex and intimacy

• Cycle irregularity and fertility. Anovulation is the leading cause of subfertility in PCOS. It is a fertility difficulty, not infertility: most people with PCOS who want a pregnancy achieve one, and ovulation induction with letrozole is first-line — the landmark PPCOS II trial (Legro et al., NEJM, 2014) showed letrozole produced higher live birth rates (27.5%) than clomiphene (19.1%). Because ovulation is unpredictable rather than absent, contraception is still needed if pregnancy is not wanted.
• Sexual function. Meta-analyses (e.g. Zhao et al., 2019, pooling FSFI studies) find modestly lower sexual function scores in PCOS, driven mainly by arousal, desire and satisfaction domains. The strongest mediators are body image distress, hirsutism and depression rather than androgen levels themselves.
• Mental health. The 2023 guideline reports moderate-to-severe depressive symptoms in around 25–35% and anxiety symptoms in up to 42% — substantially above background rates — and recommends routine screening at diagnosis.
• Body image. Hirsutism, acne, hair thinning and weight changes are consistently associated with lower sexual confidence. This is a treatable target: hair-reduction treatment and dermatological care improve quality-of-life scores independently of metabolic change.

Management relevant to intimacy

• Combined hormonal contraception regulates bleeding, protects the endometrium and reduces androgenic symptoms. No specific pill has been shown superior; the guideline advises against routinely using 35 µg ethinylestradiol with cyproterone acetate first-line due to VTE risk.
• Metformin helps metabolic parameters and cycle regularity, particularly with a BMI above 25.
• Lifestyle change improves ovulation and metabolic markers; the guideline is explicit that no single diet is superior and that weight-centric advice should avoid stigmatising language, which itself worsens outcomes.
• Endometrial protection matters. Fewer than four bleeds a year warrants clinician review — long-term unopposed oestrogen raises endometrial cancer risk two- to sixfold.
• Screening for type 2 diabetes, lipids and blood pressure is recommended, with OGTT preconception or every 1–3 years.

What is not established

Claims that inositol, keto diets or "PCOS supplements" reverse the condition go beyond the evidence; myo-inositol has some supportive trial data for ovulation but the 2023 guideline rates the certainty as low. There is no cure, but the symptoms that most affect intimacy are individually treatable.

When to see a clinician

Fewer than four periods a year, new or fast-progressing hirsutism or voice change, trying to conceive for 6–12 months without success, or persistent low mood.

Sources

• Teede HJ et al., International Evidence-Based Guideline for the Assessment and Management of PCOS, 2023 (Monash/ESHRE/ASRM).
• WHO PCOS fact sheet, 2023.
• Legro RS et al., New England Journal of Medicine, 2014 (PPCOS II letrozole trial).
• Zhao S et al., systematic review of sexual function in PCOS, 2019.